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wald, HDLc, glucose, triglycerides); and resources utilization
(specialist referrals, medical visits, drugs, tests). A logistic regres-
sion analysis was used to correct the model (IC as the dependent
variable). Costs were contrasted by a multivariate ANCOVA
analysis with marginal means estimation (Bonferroni-adjust),
using SPSS 12.0 and a statistical signiﬁcance of p < 0.05.
RESULTS: 5014 patients were evaluated; mean age was 64.6 ±
12.1; 50.3% were men; 16.1% had a history of a CVE and
27.4% had IC (CI95%:26.2–28.6%). Suffering a CVE (OR =
1.2; CI95%:1.0–1.4; p = 0.021), smoking (OR = 1.2;
CI95%:1.0–1.4; p = 0.017) and retinopathy (OR = 1.5;
CI95%:1.3–1.7; p = 0.000) were independently related with IC.
Clinical parameters and resources utilization were different in IC
vs. good control patients: glucose 181.7 ± 61.8 vs. 129.1 ± 32.0
mg/dl (p = 0.000); LDLc 122.4 ± 38.0 vs. 119.7 ± 35.48 mg/dl
(p = 0.018); mean number of oral antidiabetics was 1.3 ± 0.8 vs.
1.2 ± 0.6 (p = 0.002); and insulins 0.5 ± 0.6 vs. 0.1 ± 0.4 (p =
0.000). Total cost/patient/year adjusted with covariance was
1.953.86€ (EE = 73.7) in patients with inadequate control versus
1.747.48€ (EE = 36.2) with good control (p = 0.03). The phar-
maceutical cost represents a 74.2% overall resources utilization
costs in both good and inadequate controlled patients. CON-
CLUSIONS: Smoking, CVE and retinopathy were independently
related with inadequate glycemic control. Uncontrolled diabetic
patients have a worse lipid proﬁle and a higher glucose level
despite a higher use of oral antidiabetics and insulin, and repre-
sent a higher cost/patient/year. General practice centres should
promote speciﬁc interventions to improve glycemic control in
diabetic patients.
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OBJECTIVES: Based on the type 2 diabetes cohort of the
DETECT study (Curr Med Res and Opinion; 2005; 21/4:
619–29) simulations with the EAGLE Diabetes Model (Diab
Technology & Therapeutics; 2006; 8/2: 219–36) were con-
ducted. Development of long-term complications was compared
with respect to different treatment targets for HbA1c. Addition-
ally, the outcome for a mixed patient population typically for a
general practice was assessed. METHODS: The Economic
Assessment of Glycemic Control and Longterm Effects (EAGLE)
model simulates long-term effects of diabetes treatment and
related costs. Baseline characteristics of the simulation cohorts
corresponded to type 2 patients of the DETECT study with
HbA1c > 9%: age 63 ± 11 years, diabetes duration 9 ± 7 years,
49% male, hypertension prevalence 71%, mean HbA1c 10,1 ±
1,3%. Three cohorts with different HbA1c targets were deﬁned:
a) no change; b) 8%; and c) 6.4%. A fourth cohort was com-
posed of 25% patients with target a) 60% target; b) and 15%;
and target c). All cohorts achieve respective targets within one
year followed by a yearly increase of 0.2%. Simulations were
run with 1000 patients over 10 years. RESULTS: The relative
risk reduction comparing cohort b versus no change was 19%
(MI); 17% (stroke); 12% (PAD); 7% (prolif. retinopathy); and
4% (ESRD). A treatment target according to the German dia-
betes guideline (c versus a) resulted in reductions of 30%, 27%,
20%, 11%, and 6%, respectively. Analysing the mixed cohort
demonstrated that treatment effects were similar to the results of
cohort b. CONCLUSIONS: The simulations based on a German
diabetes population demonstrate the long-term effects of various
treatment targets for HbA1c. Although a steady re-increase of
HbA1c values was assumed a signiﬁcant reduction in micro- and
macrovascular events can be achieved. Simulations of a mixed
cohort correlate to real world patient groups and could be used
for cost estimations in practice settings.
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OBJECTIVE: to assess the economic and epidemiologic impact
of diabetes in Campania a region of approximately 5.7 million
inhabitants in the south of Italy. METHOD: we collected, from
an electronic database, all prescriptions for antidiabetic drugs
reimbursed in the ﬁrst half year of 2005 in 8 local health author-
ities (60% of the overall population) of Campania. The diabetic
cohort was deﬁned as the population of subjects receiving at least
one prescription of an antidiabetic agent, classiﬁed according to
their therapeutic role using Anatomic Therapeutic Chemical
(ATC) classiﬁcation. We identiﬁed 3 groups: who received only
insulin (A) or only oral blood glucose lowering drugs (B) or both
(C). Drugs cost and drugs consumption were quantiﬁed using
NHS prospective (expressed in Euro 2005) and Deﬁned Daily
Dose system (DDD) respectively. RESULTS: The diabetic cohort
included 200,070 subjects (5.7% of the observed population):
15.3% group A (mean age 62.7 ± 17.9 y.o., 0.78 M/F), 78.5%
group B (mean age 65.7 ± 12.2 y.o., 0.85 M/F) and 6.2% group
C (mean age 66.5 ± 11.1 y.o., 0.57 M/F). The mean
drug/cost/patient was: 524.6€ group A (36.6% insulin, 27.1%
cardiovascular drugs), €290.4 group B (11.1% oral hypo-
glycemic drugs, 47.1% cardiovascular drugs) and €649.8 group
C (25.7% insulin, 5.4% oral hypoglycemic drugs, 34.6% car-
diovascular drugs). Total cost for diabetic patients represents
17.8% of the total expenditures. CONCLUSION: Chronic-
degenerative pathologies, such as diabetes, implies a relevant
social and economic impact. Expenses that are associated to the
treatment and the prevention of complications, in particular car-
diovascular problems, are registered among the main items listed
in the health care budget. Among diabetics patients the high use
of drugs for cardiovascular problems is the cost driver.
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OBJECTIVE: This study is to investigate the impact of the
National Health Insurance (NHI) reimbursement price on the
utilization of brand name oral hypoglycemic agents (OHAs) and
its generic counterparts for ambulatory care under an institu-
tional context characterized by a health care system being lack
of separating drug prescribing and dispensing as well as a hos-
pital system with a large outpatient department, likely resulting
in the monopsony power of hospitals over the wholesale market
of pharmaceuticals. METHODS: Data is from the National
Health Insurance Database 1997–2004 with 29,253 diabetic
patient cohort data in 7 years. Patients’ severity is measured by
the types of combination pharmacological therapy. The two-part
model was used to estimate the effect of reimbursement price on
